Text Size

A Study to Evaluate Safety and Tolerability in Patients With Metastatic Breast Cancer Receiving Treatment With Caelyx (Study P04878)(COMPLETED)

This study has been completed.
Sponsor:
Information provided by:
Schering-Plough
ClinicalTrials.gov Identifier:
NCT00736333
First received: July 25, 2008
Last updated: June 13, 2011
Last verified: June 2011
History of Changes
Results First Received: June 13, 2011  
Study Type: Observational
Study Design: Observational Model: Case-Only;   Time Perspective: Prospective
Condition: Breast Neoplasm
Intervention: Drug: Pegylated Liposomal Doxorubicin

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Pegylated Liposomal Doxorubicin Pegylated liposomal doxorubicin 50 mg/m^2 given every 4 weeks for up to 6 cycles

Participant Flow:   Overall Study
    Pegylated Liposomal Doxorubicin  
STARTED     167  
COMPLETED     56  
NOT COMPLETED     111  
Did Not Receive Drug or Not Documented                 7  
Data Missing                 2  
Tumor Progression                 75  
Toxicity                 6  
Withdrawal by Subject                 10  
Death                 7  
Not Specified                 4  



  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
Pegylated Liposomal Doxorubicin Pegylated liposomal doxorubicin 50 mg/m^2 given every 4 weeks for up to 6 cycles

Baseline Measures
    Pegylated Liposomal Doxorubicin  
Number of Participants  
[units: participants]
 		  160  
Age [1]
[units: years]
Mean ± Standard Deviation 		  62  ± 12  
Gender [2]
[units: participants]
 		 
Female     159  
Male     1  
[1] Age was calculated for the intent-to-treat (ITT) population only (those who received at least one dose of study medication).
[2] Gender information was available only for the ITT population.



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Number of Participants With Infusion Reactions (IR)   [ Time Frame: Day 1 up to Week 24 ]
  Show Outcome Measure 1

2.  Primary:   Percent of Participants Taking Premedication for Prevention of IR   [ Time Frame: Day 1, immediately prior to receiving first dose of pegylated liposomal doxorubicin ]
  Show Outcome Measure 2

3.  Primary:   Number of Participants With Pre-existing Allergic Conditions Who Experienced an IR   [ Time Frame: Cycles 1 & 3 (Week 4 & Week 12) ]
  Show Outcome Measure 3

4.  Primary:   Number of Occurrences of Palmar-plantar Erythrodysesthesia (PPE)   [ Time Frame: Up to 24 weeks ]
  Show Outcome Measure 4

5.  Primary:   Number of Times Premedications Were Given for Prevention of PPE   [ Time Frame: Day 1 up to 24 weeks ]
  Show Outcome Measure 5

6.  Secondary:   Number of Participants With Complete Response (CR) or Partial Response (PR)   [ Time Frame: Day 1 up to 24 weeks ]
  Show Outcome Measure 6


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Vice President, Late Stage Development Group Leader
Organization: Merck Sharp & Dohme Corp
e-mail: ClinicalTrialsDisclosure@merck.com


No publications provided


Responsible Party: Vice President, Late Stage Development Group Leader, Merck Sharp & Dohme Corp
ClinicalTrials.gov Identifier: NCT00736333     History of Changes
Other Study ID Numbers: P04878
Study First Received: July 25, 2008
Results First Received: June 13, 2011
Last Updated: June 13, 2011
Health Authority: Austria: Ethikkommission